Lynparza in combination with bevacizumab is indicated for the:...maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability...

"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:...in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either....a deleterious or suspected deleterious BRCA mutation...

Ovarian cancer/Fallopian Tube cancer/Primary Peritoneal cancer: NCCN Recommended Options for Maintenance After First-Line Chemotherapy:...BRCA1/2 mutated...Recommended Options...Bevacizumab + olaparib.

...- other epithelial non mucinous ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation I-3-3 at an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification....